drugset
drugset / Trial / NCT05757102

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

NCT05757102 ↗

Phase 3 Recruiting 292 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Timeline

Start
2023-04-25
Primary completion
2027-01-22
Completion
2027-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Umeclidinium Other / unclassified — Inhaled
Background Fluticasone Furoate Other / unclassified — Inhaled
Background Vilanterol Other / unclassified — Inhaled

Indications

asthma